Nicotinamide Mononucleotide (NMN) is a nucleotide derived from ribose and nicotinamide. It is a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide) — one of the most important molecules in human biology.
NAD+ is involved in over 500 enzymatic reactions. It is the fuel for sirtuins (SIRT1–SIRT7) — the longevity proteins that regulate DNA repair, inflammation, mitochondrial function, and cellular stress responses. Without adequate NAD+, these critical processes slow down.
The problem: NAD+ levels decline by approximately 50% between ages 40 and 60. This decline tracks closely with the acceleration of aging-related processes: mitochondrial dysfunction, impaired DNA repair, increased inflammation, and declining energy metabolism.
NMN research has accelerated dramatically since Dr. David Sinclair's Harvard lab published landmark mouse studies. Human trials have followed:
| Study | Dose | Duration | Key Finding |
|---|---|---|---|
| Yoshino et al., Cell Metabolism 2023 | 250 mg/day | 10 weeks | Significant increase in muscle NAD+ levels and improved insulin sensitivity in older women |
| Yi et al., Nature Aging 2023 | 300 mg/day | 60 days | Significant increase in blood NAD+ levels; improved aerobic capacity in older men |
| Liao et al., 2021 | 300 mg/day | 8 weeks | Significant NAD+ increase; improved sleep quality and reduced fatigue |
| Dollerup et al., 2020 | 1,000–2,000 mg/day | 12 weeks | Safe and well-tolerated at high doses; dose-dependent NAD+ elevation confirmed |
Dissolving NMN under the tongue bypasses first-pass liver metabolism and delivers NMN directly into the bloodstream. Studies suggest sublingual NMN appears in blood within 2–3 minutes — significantly faster than oral capsules.
Liposomal encapsulation protects NMN from GI degradation and improves cellular uptake. Bioavailability studies suggest liposomal NMN achieves comparable peak plasma levels to sublingual with capsule convenience.
Oral NMN capsules do effectively raise blood NAD+ levels as confirmed by multiple human trials. At 500–1,000mg, quality capsule NMN is a legitimate and budget-friendly choice.
| Profile | Daily Dose | Rationale |
|---|---|---|
| Under 35, performance focus | 250 mg | NAD+ decline is minimal; low dose is prophylactic |
| 35–50, general longevity | 500 mg | NAD+ decline is significant; 500mg shows strong clinical results |
| 50–65, active aging | 500–750 mg | NAD+ at ~50% of peak; higher dose supports more aggressive restoration |
| 65+, longevity protocol | 1,000 mg | Maximum clinical dose with proven safety |
| Athletes, recovery focus | 500–1,000 mg | NAD+ critical for mitochondrial ATP and post-exercise DNA repair |
Current evidence and mechanistic reasoning favor morning dosing for most users:
When NMN is converted to NAD+ via the salvage pathway, it consumes methyl groups. High-dose NMN can deplete methyl group reserves — contributing to elevated homocysteine and impaired methylation. TMG (Trimethylglycine) at 500–1,000mg directly replenishes what NMN consumes.
| Supplement | Dose | Timing | Synergy |
|---|---|---|---|
| NMN (sublingual) | 500–1,000 mg | Morning fasted | Direct NAD+ precursor |
| TMG (Trimethylglycine) | 500–1,000 mg | With NMN | Methyl group donor, prevents depletion |
| Trans-Resveratrol | 500 mg | With fat (breakfast) | SIRT1 activator — synergistic with NMN |
| Pterostilbene | 100 mg | With fat | Superior bioavailability resveratrol analog; SIRT3 activation |
| Urolithin A | 500 mg | Morning | Mitophagy — clears damaged mitochondria |
| Taurine | 2–3 g | Morning | Science 2023: taurine decline drives aging; synergistic with NMN |
| CoQ10 (Ubiquinol) | 200 mg | With fat | Mitochondrial electron transport chain support |
| Folate (5-MTHF) | 400 mcg | Morning | Methylation support alongside TMG |
| Methylcobalamin B12 | 1,000 mcg | Morning sublingual | Methylation cofactor |
Many users report increased energy, better exercise endurance, improved sleep quality, and faster recovery within 2–4 weeks. The most meaningful outcomes require consistent use over months and are best measured via bloodwork.
Multiple human studies up to 12 weeks at doses up to 2,000mg/day have found NMN to be safe with no significant adverse effects. Long-term human safety data beyond 12 months is still limited. The theoretical concern about NMN and cancer remains a topic of academic debate — no human evidence of harm has emerged.
Most practitioners do not cycle NMN — it is generally taken daily as part of an ongoing longevity protocol. Unlike peptides, there is no receptor downregulation concern with NAD+ precursors.
NMN powder and sublingual tablets are relatively stable at room temperature when stored away from heat, moisture, and light. Liposomal NMN typically requires refrigeration after opening.
Log your NAD+ precursors, get real-time interaction checking, track your biomarkers over time, and let the Health Intelligence Advisor optimize your longevity protocol.
Join the Waitlist →